Navigation Links
Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications
Date:6/29/2009

aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases

SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application on proprietary, naturally occurring, resected human tRNA synthetases. Although tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, human synthetases have naturally occurring resected variants with potent cell signaling activities that are vital to normal functioning of humans. The work at Pangu BioPharma is focused on identifying and characterizing new examples of the tRNA synthetases resectome. In just the first year of operations, Pangu BioPharma has built a strong patent portfolio that provides fundamental components of aTyr Pharma's portfolio of biotherapeutic candidates that can be used to treat a wide variety of diseases, such as cardiovascular, neurological and metabolic disorders.

Pangu BioPharma is the result of an innovative partnership between aTyr Pharma and the Hong Kong University of Science and Technology (HKUST), with project funding from the Innovation and Technology Commission (ITC) of Hong Kong. James Cai, President of Pangu BioPharma, notes that, "Hong Kong's government and universities are working together to attract exciting drug discovery and development companies to make Hong Kong a new frontier in the biotechnology industry. We based Pangu BioPharma here in Hong Kong in order to capitalize on this unique position in Asia as well as to tap into the highly educated population and support of new technology industries. We are very excited about the productivity and the science being generated by the scientists in our labs here in Hong Kong, and believe that HKUST has been an essential partner in generating this mutual success."

According to Jeff Watkins, CEO of aTyr Pharm
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
8. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc. (OTC Bulletin Board: HEWA) an online U.S. mail-order ... 12% per annum short term debt financing. The ... of $500,000, with accrued interest and principal repayable in ... interest and principal repayable in one year from its ... for any calendar month prior to December 15, 2010. ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... Inc. today announced the treatment of the first ... adhesive product, TissuGlu®. Initiation of the study marks ... the lead product toward clinical practice. ,, ... study to investigate the safety of TissuGlu and ... in abdominoplasty, or "tummy tuck," surgeries. The study ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Valeritas Announces Appointment of New CEO 12391 1Valeritas Announces Appointment of New CEO 12391 2Valeritas Announces Appointment of New CEO 12391 317 million US children live more than an hour away from trauma care 47486 117 million US children live more than an hour away from trauma care 47486 2Temporary infidelity may contribute to the stability of ancient relationships 8678 1
... Cardiovascular, Research Foundation,s ADAPT-DES Study to Quantify Causes and Cures of ... ... Volcano Corporation,(Nasdaq: VOLC ) [TCT Booth #2013 Level 2], a ... its sponsorship of the first major study designed to,examine the role ...
... TUSTIN, Calif., Oct. 22 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of cancer and,hepatitis ... has submitted a,Phase II clinical protocol with the ... study bavituximab in combination with the chemotherapy drug,docetaxel ...
Other Medicine Technology:Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 2Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 3Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 4Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4
(Date:12/16/2009)... 16 For wounded U.S. servicemen ... in Washington, D.C., the holidays can be a particularly ... travel home rely more than ever on the healing ... week, calling home just got easier for Walter Reed ... cards, which will provide hundreds of minutes of holiday ...
(Date:12/16/2009)... second, possibly deadly, attack is long-term goal, researchers say ... have developed a tool to predict whether a patient ... a first stroke. , "This is an important new ... a second stroke soon after a first stroke are ... Hakan Ay, of Massachusetts General Hospital and Harvard Medical ...
(Date:12/16/2009)... In an advance that could help ease health and ... reporting development of technology for changing the behavior of ... gateway into the environment. Their study was published in ... Helen Jarvie from the UK Centre for Ecology and ... in the production of nanoparticles particles less than ...
(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
(Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5
... Magnetic Navigation prominently featured on the HRS 2009 programST. ... STXS ) said today that the Heart Rhythm 2009 ... which its Niobe system is either featured or discussed ... include new efficacy data on the use of Stereotaxis, ...
... FRANCISCO, May 11 Today,s announcement takes shared responsibility ... are committing to share responsibility for saving $2 trillion ... they succeed, affordable coverage for all is within our ... coverage based on universal responsibility. We are pleased ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... neutral, global, multidisciplinary association of professionals involved in the lifecycle ... Career Center--a highly targeted resource for online employment connections. ... ... 11, 2009 -- The Drug Information Association (DIA) , ...
... Thermofocus(R) 5-in-1WESTON, Fla., May 11 American Scientific Resources, ... for the first quarter ending March 31, 2009. ... sales of $263,603 for the first quarter of 2009, ... first quarter of 2008.The sales increase was predominantly due ...
... Inc. (NasdaqGM: SMBL) will hold its annual meeting of stockholders ... the St. Julien Hotel (Fandango Room), 900 Walnut Street, Boulder, ... business on April 1, 2009, are entitled to attend and ... About Smart Balance, Inc. , Smart Balance, Inc. ...
Other Medicine News:Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 17.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
Medicine Products: